The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EW | +11.12% | -1.48% | -0.3% | +5,817% |
| S&P | +14.29% | +86.82% | +13.3% | +355% |
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
Investors trade on potential rather than trailing results, and they found the company's top-line guidance wanting.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.55B | 14.7% |
| Gross Profit | $1.22B | 13.2% |
| Gross Margin | 78.29% | -1.0% |
| Market Cap | $45.66B | 14.9% |
| Market Cap / Employee | $2.89M | 0.0% |
| Employees | 15.8K | 0.0% |
| Net Income | $292.30M | -19.3% |
| EBITDA | $472.30M | 14.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.69B | -27.0% |
| Accounts Receivable | $693.30M | -3.2% |
| Inventory | 1.1K | 3.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $673.50M | -1.3% |
| Short Term Debt | $26.80M | 10.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.23% | -2.8% |
| Return On Invested Capital | 18.44% | -2.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $516.20M | 72.1% |
| Operating Free Cash Flow | $573.70M | 63.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 50.78 | 48.43 | 53.39 | 33.11 | -29.04% |
| Price to Book | 4.57 | 4.27 | 4.53 | 4.34 | -18.87% |
| Price to Sales | 7.64 | 7.69 | 8.09 | 7.74 | 15.36% |
| Price to Tangible Book Value | 6.25 | 6.06 | 6.39 | 6.02 | -11.11% |
| Price to Free Cash Flow TTM | 150.79 | 67.29 | 78.21 | 56.64 | -25.91% |
| Enterprise Value to EBITDA | 103.32 | 90.46 | 93.17 | 89.79 | 3.48% |
| Free Cash Flow Yield | 0.7% | 1.5% | 1.3% | 1.8% | 34.97% |
| Return on Equity | 17.2% | 16.7% | 15.7% | 13.6% | -24.22% |
| Total Debt | $700.00M | $699.40M | $702.60M | $700.30M | -0.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
